脑淀粉样血管病的核心脑脊液生物标志物谱:更新的荟萃分析
该更新的荟萃分析纳入8项研究,比较散发性脑淀粉样血管病(CAA)与对照组及阿尔茨海默病(AD)患者的5种核心脑脊液生物标志物。CAA患者脑脊液Aβ42、Aβ40、Aβ38较对照组降低,T-tau和P-tau较对照组升高;Aβ40和Aβ38可较强区分CAA与AD,而Aβ42无差异。作者认为特定脑脊液标志物模式可能作为CAA的分子生物标志物。
要点
- CAA患者脑脊液Aβ42、Aβ40、Aβ38较对照组降低,T-tau和P-tau较对照组升高。
- Aβ40和Aβ38可较强区分CAA与AD,Aβ42在两组间无显著差异。
- CAA患者T-tau和P-tau较AD患者降低,可能有助于鉴别。
核心结论
- 特定脑脊液Aβ42、Aβ40、Aβ38、T-tau和P-tau模式可能作为CAA的分子生物标志物,在研究和临床环境中提供改善特定场景临床诊断路径的潜力。
研究设计与样本
- 系统检索PubMed,纳入报告散发性CAA(基于Boston标准)与对照组和/或AD患者脑脊液生物标志物的合格研究,采用随机效应荟萃分析评估均值比(RoM)。
- 共纳入8项研究,包含11个CAA队列(n=289)、9个对照队列(n=310)和8个AD队列(n=339)。
- 总体纳入研究基于评估工具为中等质量。
主要发现
- CAA较对照组:脑脊液Aβ42的RoM为0.46(95% CI 0.38-0.55,p<0.0001),Aβ40为0.70(95% CI 0.63-0.78,p<0.0001),Aβ38为0.71(95% CI 0.56-0.89,p=0.003)。
- CAA较对照组:脑脊液T-tau的RoM为1.56(95% CI 1.32-1.84,p<0.0001),P-tau为1.31(95% CI 1.13-1.51,p<0.0001)。
- CAA与AD区分:脑脊液Aβ40的RoM为0.76(95% CI 0.69-0.83,p<0.0001),Aβ38为0.55(95% CI 0.38-0.81,p<0.0001),Aβ42为1.00(95% CI 0.81-1.23,p=0.970)。
- CAA与AD比较:脑脊液T-tau的RoM为0.64(95% CI 0.58-0.71,p<0.0001),P-tau为0.64(95% CI 0.58-0.71,p<0.0001)。
临床怎么用
- 作者认为特定脑脊液生物标志物模式可能作为CAA的分子生物标志物,用于研究和临床环境,并可能改善特定场景的临床诊断路径。
局限性
- 总体纳入研究基于评估工具为中等质量。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: There is a clear need to characterize and validate molecular biomarkers of cerebral amyloid angiopathy (CAA), in an effort to improve diagnostics, especially in the context of patients with Alzheimer disease (AD) receiving immunotherapies (for whom underlying CAA is the driver of amyloid-related imaging abnormalities). We performed an updated meta-analysis of 5 core CSF biomarkers (Aβ42, Aβ40, Aβ438, total tau [T-tau], and phosphorylated tau [P-tau]) to assess which of these are most altered in sporadic CAA. METHODS: We systematically searched PubMed for eligible studies reporting data on CSF biomarkers reflecting APP metabolism (Aβ42, Aβ40, Aβ38), neurodegeneration (T-tau), and tangle pathology (P-tau), in symptomatic sporadic CAA cohorts (based on the Boston criteria) vs control groups and/or vs patients with AD. Biomarker performance was assessed in random-effects meta-analysis based on ratio of mean (RoM) biomarker concentrations in (1) patients with CAA to controls and (2) CAA to patients with AD. RoM >1 indicates higher biomarker concentration in CAA vs comparison population, and RoM <1 indicates higher concentration in comparison groups. RESULTS: 8 studies met inclusion criteria: a total of 11 CAA cohorts (n = 289), 9 control cohorts (n = 310), and 8 AD cohorts (n = 339). Overall included studies were of medium quality based on our assessment tools. CAA to controls had lower mean level of all amyloid markers with CSF Aβ42, Aβ40, and Aβ38 RoMs of 0.46 (95% CI 0.38-0.55, p < 0.0001), 0.70 (95% CI 0.63-0.78, p < 0.0001), and 0.71 (95% CI 0.56-0.89, p = 0.003), respectively. CSF T-tau and P-tau RoMs of patients with CAA to controls were both greater than 1: 1.56 (95% CI 1.32-1.84, p < 0.0001) and 1.31 (95% CI 1.13-1.51, p < 0.0001), respectively. Differentiation between CAA and AD was strong for CSF Aβ40 (RoM 0.76, 95% CI 0.69-0.83, p < 0.0001) and Aβ38 (RoM 0.55, 95% CI 0.38-0.81, p < 0.0001), but not Aβ42 (RoM 1.00; 95% CI 0.81-1.23, p = 0.970). For T-tau and P-tau, average CSF ratios in patients with CAA vs AD were 0.64 (95% CI 0.58-0.71, p < 0.0001) and 0.64 (95% CI 0.58-0.71, p < 0.0001), respectively. DISCUSSION: Specific CSF patterns of Aβ42, Aβ40, Aβ38, T-tau, and P-tau might serve as molecular biomarkers of CAA, in research and clinical settings, offering the potential to improve the clinical diagnostic approach pathway in specific scenarios.
引用
- Charidimou A, Boulouis G. Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis. Neurology. 2024. PMID: 39270153. doi:10.1212/WNL.0000000000209795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。